FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1676-1678 June 1, 2000 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Related Article by Yeghiazarians, Y.

To the Editor: Yeghiazarians and colleagues (Jan. 13 issue)¹ did not mention 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins) in their interesting review of unstable angina pectoris. Evidence from a secondary-prevention study — the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study — involving more than 9000 patients, 36 percent of whom had been given a diagnosis of unstable angina between 3 and 36 months before study entry, showed that pravastatin significantly lowered the rate of hospitalization for unstable angina pectoris, with a relative reduction in risk of 12 percent (95 percent confidence interval, 4 to 19 percent; P=0.005).² This relative . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.